Conservation of amino acids in human rhinovirus 3C protease correlates with broad-spectrum antiviral activity of rupintrivir, a novel human rhinovirus 3C protease inhibitor.
The picornavirus 3C protease is required for the majority of proteolytic cleavages that occur during the viral life cycle. Comparisons of published amino acid sequences from 6 human rhinoviruses (HRV) and 20 human enteroviruses (HEV) show considerable variability in the 3C protease-coding region but strict conservation of the catalytic triad residues. Rupintrivir (formerly AG7088) is an irreversible inhibitor of HRV 3C protease with potent in vitro activity against all HRV serotypes (48 of 48), HEV strains (4 of 4), and untyped HRV field isolates (46 of 46) tested. To better understand the relationship between in vitro antiviral activity and 3C protease-rupintrivir binding interactions, we performed nucleotide sequence analyses on an additional 21 HRV serotypes and 11 HRV clinical isolates. Antiviral activity was also determined for 23 HRV clinical isolates and four additional HEV strains. Sequence comparison of 3C proteases (n = 58) show that 13 and 11 of the 14 amino acids that are involved in side chain interactions with rupintrivir are strictly conserved among HRV and HEV, respectively. These sequence analyses are consistent with the comparable in vitro antiviral potencies of rupintrivir against all HRV serotypes, HRV isolates, and HEV strains tested (50% effective concentration range, 3 to 183 nM; n = 125). In summary, the conservation of critical amino acid residues in 3C protease and the observation of potent, broad-spectrum antipicornavirus activity of rupintrivir highlight the advantages of 3C protease as an antiviral target.
Binford
S L
SL
Department of Virology, Pfizer Global Research and Development, 10777 Science Center Dr., San Diego, CA 92121, USA.
Maldonado
F
F
Brothers
M A
MA
Weady
P T
PT
Zalman
L S
LS
Meador
J W
JW
Matthews
D A
DA
Patick
A K
AK
D000086042:3C Viral Proteases; D000596:Amino Acids / Q000378:metabolism*; D000998:Antiviral Agents / Q000494:pharmacology*; D017124:Conserved Sequence; D003546:Cysteine Endopeptidases / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*; D006367:HeLa Cells; D006801:Humans; D007555:Isoxazoles / Q000494:pharmacology*; D008969:Molecular Sequence Data; D010649:Phenylalanine / Q000031:analogs & derivatives; D011480:Protease Inhibitors / Q000494:pharmacology*; D011760:Pyrrolidinones / Q000494:pharmacology*; D012367:RNA, Viral / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012229:Rhinovirus / Q000201:enzymology* / Q000235:genetics*; D014633:Valine / Q000031:analogs & derivatives; D014764:Viral Proteins / Q000187:drug effects / Q000235:genetics / Q000378:metabolism*
D000596:Amino Acids; D000998:Antiviral Agents; D007555:Isoxazoles; D011480:Protease Inhibitors; D011760:Pyrrolidinones; D012367:RNA, Viral; D014764:Viral Proteins; D010649:Phenylalanine; D003546:Cysteine Endopeptidases; D000086042:3C Viral Proteases; D014633:Valine; C118874:rupintrivir